AstraZeneca, Oxford Aim to Produce Omicron-Targeted Vaccine

A doctor shows vials of AstraZeneca's COVID-19 vaccine in his general practice facility, as the spread of the coronavirus disease (COVID-19) continues, in Vienna, Austria, on Leonhard Foeger/Reuters

AstraZeneca Plc said on Tuesday it is working with Oxford University to produce a vaccine for the Omicron coronavirus variant, joining other vaccine-makers who are looking to develop the variant-specific vaccine.

“Together with Oxford University, we have taken preliminary steps in producing an Omicron variant vaccine, in case it is needed and will be informed by emerging data,” a spokesperson for the company said in a statement.